ADA AS MAIN BIOCHEMICAL MARKER IN PATIENTS WITH TUBERCULOUS EFFUSION
ADA in tuberculous effusion
Abstract
Tuberculous pleuritis (TP) is one of the most common extra-pulmonary tuberculosis form. Because of tuberculous pleurisy is hard to diagnose due to slow course of disease and lack of specificity in symptoms and diagnostic methods. In that reason, we need multidisciplinary approach and efficient biomarkers. Acid-fast bacilli (AFB) staining, cultures and pathophysiological biopsy finding from the majority of patients are positive only in less than 10%. Löwenstein culture results need time about 6-8 weeks what delays diagnosis. Adenosine deaminase (ADA) is biomarker with high sensitivity and specificity (more than 90%) and considered as gold standard of biomarkers in the diagnosis of TP. It is very hard to distinguish malignant from TP with lymphocyte predomination, but in patient with malignant pleural effusion the level of ADA is decreased, opposite from TP. ADA in pleural punctate is a fast, simple, efficient and economical way for clarification the etiology of the pleural effusion as tuberculous pleurisy. Also, many studies have proved the role of ADA in the response to treatment for tuberculosis at follow up period
References
1. Jany B, Welte T. Pleural Effusion in Adults-Etiology, Diagnosis, and Treatment. DtschArztebl Int. 2019 May 24;116(21):377-386 Frost N et al. Indwelling pleural catheters for non-malignant pleural effusions: report on a single centre's 10 years of experience. BMJ Open Respir Res 2020; 7.
3. Huyen PT et al. Exploring the value of pleural fluid biomarkers for complementary pleural effusion disease examination. Computational Biology and Chemistry. Volume 94, October 2021, 107559
4. Porcel JM. Biomarkers in the diagnosis of pleural diseases: a 2018 update. TherAdvRespir Dis. 2018 Jan-Dec;12:1753466618808660
5. Shaw JA, Koegelenberg CFN. Pleural Tuberculosis. Clin Chest Med. 2021 Dec;42(4):649-666.
6. Shaw JA, Diacon AH, Koegelenberg CFN. Tuberculous pleural effusion. Respirology. 2019 Oct;24(10):962-971.
7. Porcel JM. Pleural fluid biomarkers: beyond the Light criteria. Clin Chest Med. 2013 Mar;34(1):27-37
8. Ren ZH, Xu L. Biomarkers of Distinguishing Neutrophil-Predominant Tuberculous Pleural Effusion from Parapneumonic Pleural Effusion. Am J Med Sci. 2021 Apr;361(4):469-478.
9. Xi S, Sun J, Wang H, Qiao Q, He X. Diagnostic Value of Model-Based Iterative Algorithm in Tuberculous Pleural Effusion. J Healthc Eng. 2022 Feb 9;2022:7845767.
10. Petborom P, Dechates B, Muangnoi P. Differentiating tuberculouspleuritis from other exudative lymphocytic pleural effusions. Ann Palliat Med. 2020 Sep;9(5):2508-2515
11. Chen KY etal.Novel biomarker analysis of pleural effusion enhances differentiation of tuberculous from malignant pleural effusion. Int Journal of Gen Medicine. 2016; 9: 183–189
12. Lo Cascio CM, Kaul V, Dhooria S, Agrawal A, Chaddha U. Diagnosis of tuberculous pleural effusions: A review. Respir Med. 2021 Nov;188:106607.
13. Ali MS, Light RW, Maldonado F. Pleuroscopy or video-assisted thoracoscopic surgery for exudative pleural effusion: a comparative overview. J Thorac Dis. 2019 Jul;11(7):3207-3216.
14. Javadi J et al. Multiplex Soluble Biomarker Analysis from Pleural Effusion. Biomolecules 2020, 10, 1113
15. Aggarwal AN, Agarwal R, Sehgal IS, et al..Adenosine deaminase for diagnosis of tuberculous pleural effusion: a systematic review and meta-analysis. PLoS One. 2019;14(3):e0213728
16. Na F, Wang Y, Yang H, Guo L, Liang X, Liu D, Zhang R. Performance of adenosine deaminase in detecting paediatric pleural tuberculosis: a systematic review and meta-analysis. Ann Med. 2022 Dec;54(1):3129-3135.
17. Gao L, Wang W, Zhang Y, Hu X, An J, Li Y et al. Adenosine deaminase-based measurement in the differential diagnosis of pleural effusion: a multicenter retrospective study. Ther Adv Respir Dis. 2023;17:17534666231155747.
18. Lee J, Park JE, Choi SH, Seo H, Lee SY, Lim JK, Yoo SS, Lee SY, Cha SI, Park JY, Kim CH. Laboratory and radiological discrimination between tuberculous and malignant pleural effusions with high adenosine deaminase levels. Korean J Intern Med. 2022 Jan;37(1):137-145.
19. Zeng T, Ling B, Hu X, Wang S, Qiao W, Gao L, Shen Y, Li D. The Value of Adenosine Deaminase 2 in the Detection of Tuberculous Pleural Effusion: A Meta-Analysis and Systematic Review. Can Respir J. 2022 Sep 10;2022:7078652.
20. Kim SB, Shin B, Lee JH, Lee SJ, Lee MK, Lee WY et al. Pleural fluid ADA activity in tuberculous pleurisy can be low in elderly, critically ill patients with multi-organ failure. BMC Pulm Med. 2020;20(1):13.
21. Kim HW, Kim KH, Shin AY, Choi JY, Ahn JH, Kim JS et al. Investigating the appropriate adenosine deaminase cutoff value for the diagnosis of tuberculous pleural effusion in a country with decreasing TB burden. Sci Rep. 2022;12(1):7586.
22. Shaw JA, Irusen EM, Diacon AH, Koegelenberg CF. Pleural tuberculosis: A concise clinical review. ClinRespir J. 2018 May;12(5):1779-1786.
23. Lin L, Li S, Xiong Q, Wang H. A retrospective study on the combined biomarkers and ratios in serum and pleural fluid to distinguish the multiple types of pleural effusion. BMC Pulm Med. 2021;21(1):95.
24. Soedarsono S, Prinasetyo KWAI, Tanzilia M, Nugraha J. Changes of serum adenosine deaminase level in new cases of pulmonary tuberculosis before and after intensive phase treatment. Lung India. 2020;37(2):126-129.
25. Saini V, Lokhande B, Jaswal S, Aggarwal D, Garg K, Kaur J. Role of serum adenosine deaminase in pulmonary tuberculosis. Indian J Tuberc. 2018 Jan;65(1):30-34.
Copyright (c) 2023 Jelena Janković, Branislav Ilic, Nataša Đurđević, Aleksandar Jandric
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.